Feyera Gemeda | Infectious Diseases | Outstanding Scientist Award

Assoc. Prof. Dr. Feyera Gemeda | Infectious Diseases | Outstanding Scientist Award

Associate Professor | Dima Jimma university | Ethiopia

Assoc. Prof. Dr. Feyera Gemeda Dima is a distinguished researcher and academic with extensive experience in Infectious Diseases, Medical Mycology, and Medicine. He has demonstrated excellence in teaching, research, and mentorship at both national and international levels, fostering the development of students and early-career researchers. His work emphasizes innovation in scientific research, editorial contributions, and leadership in grant assessment and curriculum development. He has contributed significantly to global collaborations and serves as a Chief Scientist and Global Assessor, reflecting his commitment to advancing scientific knowledge. His research focuses on improving understanding and management of infectious diseases, with the potential to influence public health strategies. Prof. Gemeda’s dedication to integrating innovative approaches and interdisciplinary perspectives underscores his capacity for impactful contributions in the field.

Profile:  Google Scholar

Featured Publications

1. T. Gizaw and F. G. Dima, “Assessment of problems and constraints associated with artificial insemination service in the two selected districts of Arsi zone,” Journal of Harmonized Research in Medical and Health Sciences, vol. 3, no. 1, pp. 14–37, 2016.

2. A. Edao, F. G. Dima, and F. B. Deressa, “Prevalence of bovine cysticercosis and status of human taeniasis in and around Asella town, Tiyoworeda, south east Ethiopia,” Glob J Med Res, vol. 16, pp. 18–26, 2016.

3. F. Gemeda, “Prevalence of bovine Trypanosomosis in and around Nekemte areas, east Wollega zone, Ethiopia,” Open Access Library Journal, vol. 2, no. 05, p. 1, 2015.

4. D. T. Legesse and F. Gemeda, “Comparison of two parasitological tests and post mortem examination to detect prevalence of bovine fasciolosis at Ambo Town Municipal Abattoir, West Shewa Zone, Ethiopia,” Open Access Library Journal, vol. 2, no. 8, pp. 1–5, 2015.

5. F. G. Dima and T. Fikedu, “Review on infectious bovine keratoconjunctivitis,” J Bacteriol Infect Dis, vol. 4, no. 4, pp. 1–6, 2021.

Dr. Gemeda’s work advances the understanding and control of infectious diseases, providing evidence-driven insights that strengthen public health systems and guide global disease management strategies.

Maria Morales-Suarez-Varela | Medicine and Pharmacy | Best Researcher Award

Prof. Dr. Maria Morales-Suarez-Varela | Medicine and Pharmacy | Best Researcher Award
Full professor | University of Valencia | Spain

Prof. Dr. Maria Morales-Suárez-Varela is a distinguished academic and researcher specializing in public health, preventive medicine, nutrition, and environmental epidemiology. Serving as a Full Professor at the Universitat de València, she has made outstanding contributions to advancing scientific understanding of the relationships between environmental exposures, nutrition, and population health. She holds a Doctorate and a Licentiate in Medicine and Surgery, with advanced expertise in preventive and public health sciences. As Principal Investigator of prominent research groups within the CIBER of Epidemiology and Public Health and the Universitat de València, she has led numerous national and international projects funded by competitive public and private agencies. Her scholarly impact is reflected in hundreds of high-quality publications indexed in leading databases, an extensive record of citations, and a strong h-index that underscores her scientific influence. She has supervised numerous doctoral theses and has presented extensively at global conferences. Her research integrates epidemiological evidence with policy-relevant health solutions, with special focus on maternal and child health, dietary patterns, environmental risks, and population well-being. Recognized for her leadership and excellence, she has received multiple distinctions for research merit and contributes actively to scientific networks, editorial boards, and peer-review committees. Prof. Morales-Suárez-Varela exemplifies academic rigor, innovation, and dedication to public health advancement, making her a highly deserving candidate for this award.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Morales-Suárez-Varela, M., et al. (2025). Effect of the Mediterranean diet on BMI and body composition: A preliminary pre-post intervention study in pediatric overweight patients. Nutrition.

2. Morales-Suárez-Varela, M., et al. (2025). Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients. Colorectal Disease.

3. Morales-Suárez-Varela, M., et al. (2025). Systematic review of prenatal exposure to PM2.5 and its chemical components and their effects on neurodevelopmental outcomes in neonates.

4. Morales-Suárez-Varela, M., et al. (2025). Helminth/Protozoan coinfections in chronic fascioliasis cases in human hyperendemic areas: High risk of multiparasitism linked to transmission aspects and immunological, environmental and social factors. Tropical Medicine and Infectious Disease.

5. Morales-Suárez-Varela, M., et al. (2025). Analysis of demographic and health characteristics and adherence to the Mediterranean diet in pregnant women: MEDAS questionnaire. Semergen.

Prof. Dr. Maria Morales-Suárez-Varela’s research advances global understanding of how environmental, nutritional, and lifestyle factors influence public health outcomes. Her work bridges science and policy, driving innovations that promote healthier populations, sustainable healthcare practices, and evidence-based prevention strategies worldwide.

Judita Kinkorova | Biobanking | Best Researcher Award 

Assoc. Prof. Dr. Judita Kinkorova | Biobanking | Best Researcher Award 

Senior Scientist | University Hospital in Pilsen | Czech Republic

Assoc. Prof. Dr. Judita Kinkorová is a leading researcher in biobanking, personalized medicine, and preventive healthcare, recognized for her significant contributions to international research collaboration. She has successfully coordinated major European research initiatives, including FP7 and Horizon 2020 projects, and has played a pivotal role in developing hospital-integrated biobanks that strengthen biomedical research infrastructure. Her active participation in scientific societies and editorial boards reflects her influence and thought leadership in advancing precision health. Dr. Kinkorová’s work integrates scientific rigor with strategic collaboration, mentorship, and policy engagement, demonstrating strong potential for further innovation in genomic and biomarker research, sustainable biobanking, and cross-border scientific partnerships. Her research output is substantial, comprising 47 Scopus-indexed publications, cited 852 times by 744 documents, with an h-index of 12, highlighting the measurable impact and quality of her contributions to the field.

Profile: Scopus | ORCID

Featured Publications

1. J. Kinkorová and O. Topolčan, “Biobanks in the era of big data: objectives, challenges, perspectives, and innovations for predictive, preventive, and personalised medicine,” EPMA Journal, 2020.

2. J. Kinkorová, O. Topolčan, and R. Kučera, “Informed Consent in the Newly Established Biobank,” International Journal of Environmental Research and Public Health, 2019.

3. J. Kinkorová and O. Topolčan, “Biobanks in Horizon 2020: sustainability and attractive perspectives,” EPMA Journal, 2018.

4. “The 44th Congress of the International Society of Oncology and Biomarkers: Rio de Janeiro, Brazil, 7-10 September 2017,” Future Medicine, 2018.

5. J. Kinkorová and O. Topolčan, “Biobanks – European infrastructur | Biobanky – Evropská infrastruktura,” Casopis Lekaru Ceskych, 2016.

Laura Garriga-Grimau | Medicine and Dentistry | Best Researcher Award

Dr. Laura Garriga-Grimau | Medicine and Dentistry | Best Researcher Award

Physician at Hospital Universitari Vall d’Hebron, Spain

Dr. Laura Garriga-Grimau is a dedicated pediatric pulmonologist based at Vall d’Hebron University Hospital in Barcelona, Spain. She specializes in bronchiectasis, cystic fibrosis, and other chronic pediatric lung conditions. Her work bridges clinical practice, academic research, and teaching. She is actively involved in multiple international research collaborations, including the European Respiratory Society (ERS) and the Child-BEAR-Net Registry. A strong advocate for improving respiratory care in children, Dr. Garriga-Grimau has authored numerous peer-reviewed publications and contributed to global studies shaping pediatric lung health guidelines. Her academic and clinical background is enriched by international clinical training in Australia and active teaching roles at the Autonomous University of Barcelona. Known for her collaborative leadership and deep scientific insight, she continues to contribute to innovation in pediatric respiratory medicine while mentoring future healthcare professionals. Her work is both evidence-driven and patient-centered, earning her a growing reputation in European and global pediatric research communities.

🔹 Professional Profile 

Scopus Profile
ORCID Profile 

🏆Strengths for the Award

Dr. Laura Garriga-Grimau has demonstrated a strong commitment to advancing pediatric respiratory medicine through a blend of clinical excellence, academic research, and international collaboration. Her specialization in bronchiectasis and cystic fibrosis has positioned her as a key contributor in areas that are often underrepresented in pediatric research. She currently holds leadership roles in prominent research initiatives, such as Chair of the ERS Task Force on Transitioning Adolescents with Bronchiectasis, and Deputy Co-Chair of the Child-BEAR-Net Registry, reflecting the recognition she commands within global respiratory research communities. These roles not only highlight her scientific insight but also her ability to coordinate multinational teams and influence clinical policy development.

Her publication record is both prolific and impactful, including research in The Lancet Respiratory Medicine, New England Journal of Medicine, and other peer-reviewed international journals. Dr. Garriga-Grimau has contributed to high-quality, multi-center studies and registries that address real-world challenges in diagnosis, treatment, and care models for pediatric lung diseases. Notably, her involvement in the SHIP-CT trial and the Spanish Pediatric Bronchiectasis Registry demonstrates her ability to participate in and lead complex clinical research initiatives with both academic and translational value. Her research outputs are data-driven, well-cited, and directly relevant to improving health outcomes in children globally.

In addition to her research achievements, Dr. Garriga-Grimau has actively bridged the gap between academia and clinical practice. She contributes as a faculty member in the Pediatric Pulmonology Master’s program at the Autonomous University of Barcelona and has been involved in mentoring and training future clinicians and researchers. Her international clinical exposure, including a bronchiectasis fellowship in Australia, enhances the global relevance and cultural sensitivity of her work. This combination of academic productivity, clinical innovation, and leadership in international research networks makes her a well-rounded and highly deserving candidate for the Best Researcher Award.

🎓Education

Dr. Laura Garriga-Grimau completed her medical education and pediatric residency through the Spanish MIR system at the University of Barcelona, one of Spain’s leading academic medical centers. Following her pediatric training, she pursued specialized academic advancement through a Master’s degree in Pediatric Pulmonology from the Autonomous University of Barcelona (UAB), where she later became a faculty member. Her passion for research and respiratory medicine led her to complete a PhD focused on cystic fibrosis at Vall d’Hebron University Hospital, contributing significant findings to the field. In addition to her formal education, Dr. Garriga-Grimau enriched her academic and clinical knowledge with a training fellowship in bronchiectasis at the Queensland Children’s Hospital in Australia. Her continuous pursuit of learning, from clinical practice to translational research, has equipped her with a strong foundation in evidence-based medicine and multidisciplinary collaboration, shaping her into a leader in pediatric respiratory care both in Spain and internationally.

💼 Experience

Dr. Laura Garriga-Grimau has built an extensive and dynamic professional career in pediatric pulmonology, anchored at Vall d’Hebron University Hospital. She serves as a consultant in the Pediatric Pulmonology Department, where she treats complex respiratory conditions, including cystic fibrosis and bronchiectasis. Her clinical experience is complemented by her academic involvement as a lecturer in the Pediatric Pulmonology Master’s program at the Autonomous University of Barcelona. She completed international clinical training in Australia, focusing on bronchiectasis, and collaborates with research networks such as the ERS, ERN-Lung, and Child-BEAR-Net. Her career integrates hands-on patient care with data-driven research, highlighting her ability to translate science into practice. In leadership roles such as Chair of the ERS Task Force on adolescent bronchiectasis transition and Deputy Co-Chair of Child-BEAR-Net, she coordinates multinational teams and projects. Her balanced experience across clinical, research, and educational domains establishes her as a well-rounded and forward-thinking physician-scientist.

🏆 Awards and Honors

While specific individual awards are not listed in her profile, Dr. Laura Garriga-Grimau’s numerous prestigious roles and peer-reviewed publications serve as strong indicators of her academic and professional recognition. She has earned notable leadership positions in internationally recognized research bodies such as the European Respiratory Society (ERS) and the Child-BEAR-Net network, which are typically awarded based on merit, contribution, and peer endorsement. She is a key author and collaborator in top-tier journals including The Lancet Respiratory Medicine and The New England Journal of Medicine—an honor in itself that reflects a high level of expertise and scientific impact. Her inclusion in global studies and research registries, as well as her involvement in shaping clinical guidelines, affirms her reputation in the field of pediatric pulmonology. Furthermore, her appointment as faculty at a major academic institution and her PhD achievements represent high academic recognition within both national and international medical communities.

🔬Research Focus on Medicine and Dentistry

Dr. Garriga-Grimau’s research centers on pediatric bronchiectasis, cystic fibrosis, and related respiratory disorders, with an emphasis on improving diagnostics, treatment protocols, and health equity in chronic pediatric lung care. She is actively involved in several major international studies and registries, including the Child-BEAR-Net Registry and SHIP-CT trial. Her research evaluates multicountry clinical variations, healthcare transitions from adolescence to adulthood, and therapy optimization for children with chronic respiratory disease. She collaborates on translational studies that influence clinical guidelines and promote standardized care across different healthcare systems. Her work particularly emphasizes underserved populations, including Indigenous communities, reflecting her commitment to inclusive, global health research. By integrating clinical experience with robust epidemiological and translational approaches, Dr. Garriga-Grimau’s research not only advances scientific understanding but also directly enhances patient outcomes. She contributes to major publications and plays key roles in shaping pediatric pulmonology’s research priorities at the European and global level.

📚 Publications Top Notes

  • First results from the international paediatric bronchiectasis registry (Child‑BEAR‑Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cross‑sectional study

    • Authors: Laura Garriga‑Grimau; Ahmad Kantar; Keith Grimwood; Charl Verwey; Refiloe Masekela; Diane Gray; Ameena Goga; Bulent Karadag; Ela Erdem Eralp; Yasemin Gokdemir; et al.

    • Year: 2025

    • Citations: 1 (as per Scopus/ResearchGate)

  • Guiding practice principles for clinicians who work with Indigenous people

    • Authors: André Schultz; Anne B. Chang; Donna M. Mason; Julie M. Marchant; Lesley A. Versteegh; Maree Toombs; Laura Garriga‑Grimau; CRE Extended Group

    • Year: 2025

  • Bronchiectasis in pediatrics

    • Authors: Laura Garriga‑Grimau; Eva Polverino; Antonio Moreno‑Galdó

    • Year: 2025

  • Implementation of the Spanish Paediatric Bronchiectasis Registry (Child‑BEAR‑es Registry)

    • Authors: Laura Garriga‑Grimau; Verónica Sanz‑Santiago; Antonio Moreno‑Galdó

    • Year: 2024

  • Improving the Diagnosis and Treatment of Paediatric Bronchiectasis Through Research and Translation

    • Authors: Anne B. Chang; Shyamali C. Dharmage; Julie M. Marchant; Gabrielle B. McCallum; Peter S. Morris; Andre Schultz; Maree Toombs; Danielle F. Wurzel; Stephanie T. Yerkovich; Keith Grimwood; Laura Garriga‑Grimau; CRE extended group

    • Year: 2024

  • Asma (book chapter)

    • Author: Laura Garriga‑Grimau

    • Year: 2022

  • Pneumònia per Streptococcus pyogenes a l’edat pediàtrica

    • Author: Laura Garriga‑Grimau

    • Year: 2022

  • The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP‑CT)

    • Authors: Harm A.W.M. Tiddens; Yuxin Chen; Eleni‑Rosalina Andrinopoulou; et al., including Laura Garriga‑Grimau

    • Year: 2022

  • Triple Therapy for Cystic Fibrosis Phe508del‑Gating and ‑Residual Function Genotypes

    • Authors: Peter J. Barry; Marcus A. Mall; Antonio Álvarez; et al., including Laura Garriga‑Grimau

    • Year: 2021

  • How abnormal is the normal? Clinical characteristics of CF patients with normal FEV₁

    • Authors: Malena Cohen‑Cymberknoh; Elad Ben Meir; Silvia Gartner; et al., including Laura Garriga‑Grimau

    • Year: 2021

  • Earlier clinical case reports (2012–2015)

    • Authors: Laura Garriga‑Grimau et al.

    • Years: 2012–2015

📌 Conclusion

Dr. Laura Garriga-Grimau exemplifies the rare combination of clinical expertise, academic leadership, and collaborative spirit essential for advancing global pediatric pulmonology. Her commitment to research excellence, her leadership in multinational registries and task forces, and her drive to improve outcomes for children with chronic respiratory diseases mark her as an innovator in the field. Whether through her patient care, her mentorship of future specialists, or her groundbreaking studies in bronchiectasis and cystic fibrosis, Dr. Garriga-Grimau continues to push the boundaries of pediatric respiratory medicine. Her contributions resonate not only within academic journals but also in real-world clinical settings across borders. As she builds on her already distinguished career, she remains a key force in shaping the future of respiratory healthcare for children worldwide. Dr. Garriga-Grimau is undoubtedly a deserving candidate for any accolade recognizing research excellence, innovation, and global impact in medicine.

Dr. Javier Crespo | Medicine and Dentistry | Best Researcher Award

Dr. Javier Crespo | Medicine and Dentistry | Best Researcher Award

Professor at IDIVAL, Spain

Professor Javier Crespo is a distinguished physician-scientist and academic leader in the field of digestive and liver diseases. Currently a Professor of Medicine at the University of Cantabria and Director of the Translational Research in Digestive Pathology group at IDIVAL, he has made significant contributions through over 400 original publications, more than 120 clinical trials, and leadership in numerous national and international research projects. With an H-index of 70 and over 30,000 citations, his work has had a profound global impact. He has played a pivotal role in national health strategies, including Spain’s Hepatitis C elimination plan, and served as President of major professional societies such as SEPD. A mentor to numerous doctoral and master’s students, he has also received multiple prestigious awards for his contributions to medicine and research. His leadership at Marqués de Valdecilla University Hospital earned repeated national recognition for excellence in digestive and hepatitis care.

Professional Profile 

Google Scholar
Scopus Profile
ORCID Profile 

Education

Professor Javier Crespo earned his Degree in Medicine and General Surgery from the University of Cantabria with an Outstanding qualification. He later obtained his Doctorate in Medicine in 1993, receiving the Extraordinary Doctorate Award for academic excellence. His formal education laid a strong foundation for a career marked by clinical rigor and academic depth. In addition to his medical qualifications, he has been accredited as a Professor by ANECA (the Spanish National Agency for Quality Assessment and Accreditation). His academic journey reflects not only excellence in performance but also an enduring commitment to scientific learning and advancement. His scholarly trajectory is rooted in a lifelong dedication to the field of hepatology and digestive pathology, with an early focus on merging basic medical science with clinical research. These formative years have played a crucial role in shaping his influential career in medicine, teaching, and research.

Professional Experience

Professor Crespo has held several prestigious positions throughout his career. He is a Professor of Medicine at the University of Cantabria and Director of the Translational Research in Digestive Pathology group at IDIVAL. He served as Head of the Digestive Service at Marqués de Valdecilla University Hospital from 2010 to 2024. Additionally, he has played strategic roles in healthcare governance, including being a member of Spain’s National Strategic Plan against Hepatitis C since 2015 and coordinator of the AEEH National Liver Health Plan Challenge 2032. His leadership extends to professional societies—he served as President of the Spanish Society of Digestive Pathology (SEPD), President of the National Digestive Commission, and Secretary of the Spanish Association for the Study of the Liver. His professional career reflects a unique blend of clinical excellence, policy leadership, academic mentoring, and research management, making him one of the most respected figures in his specialty.

Research Interest

Professor Crespo’s primary research interests center around digestive and liver diseases, with a particular focus on hepatitis C, liver cirrhosis, and inflammatory bowel diseases. He has led more than 120 clinical trials across Phases I–III and participated in 15 national and 8 international competitive research projects. His translational approach bridges laboratory findings with clinical application, especially in hepatology. Under his leadership, the IDIVAL research group has produced high-impact findings in digestive pathology and liver disease progression. He has authored over 400 original scientific articles, with a strong presence in high-impact journals. His work is cited more than 30,000 times, and he holds an H-index of 70, underscoring his global influence. He is also actively involved in supervising doctoral and postgraduate theses, reflecting his dedication to advancing the next generation of researchers in gastroenterology. His research has contributed significantly to public health, particularly in the management and elimination of hepatitis C.

Award and Honor

Professor Javier Crespo has received numerous national and international awards that recognize both his scientific excellence and public health impact. Among his most prestigious accolades are the Elimination Champions 2023 International Award, granted by the Coalition for Global Hepatitis Elimination, and the International Award at the VI LIFE Forum for HCV Elimination in Lima (2024). Nationally, he has been honored with the Commendation of the Civil Order of Health, the SEPD Gold Medal, and the ACAD Gold Medal. He was also named an Illustrious Torrelaveguense in 2024. Under his leadership, the Digestive Service at Marqués de Valdecilla University Hospital received the Best in Class Award for several consecutive years for excellence in digestive and hepatitis care. His honors reflect not only scientific merit but also his dedication to clinical service and public health leadership, making him one of the most decorated professionals in his field.

Conclusion

In conclusion, Professor Javier Crespo is a highly accomplished and impactful leader in the fields of gastroenterology and hepatology. His career combines outstanding academic achievement, clinical leadership, and translational research excellence. With more than 30,000 citations and an H-index of 70, his scientific contributions have shaped current practices in liver disease treatment and public health strategies. He has held top-level positions in hospitals, universities, research institutes, and national health commissions, evidencing his multifaceted influence. Through his mentorship, he has cultivated a generation of researchers and clinicians, further extending his legacy. His work has not only garnered national and international recognition through prestigious awards but has also led to meaningful improvements in patient care, especially in hepatitis C management. Professor Crespo exemplifies the qualities of a visionary researcher, a compassionate physician, and a dedicated educator—making him exceptionally worthy of recognition such as the Best Researcher Award.

Publications Top Notes

  • Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis

    • Authors: Not listed

    • Year: 2025

    • Citations: 3

  • Letter to the Editor: Optimizing MASLD treatment—A “lead-in phase” before resmetirom

    • Authors: Not listed

    • Year: Not listed

    • Citations: 1

  • Comprehensive Diagnosis of Viral Hepatitis in Spain: Bases for Implementation

    • Authors: Not listed

    • Year: 2025

  • Unraveling MASLD: The Role of Gut Microbiota, Dietary Modulation, and AI-Driven Lifestyle Interventions

    • Authors: Not listed

    • Year: Not listed

    • Citations: 1

  • A multisociety Delphi consensus statement on new fatty liver disease nomenclature

    • Authors: ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, …

    • Year: 2023

    • Citations: 4,096

  • Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn’s disease

    • Authors: N Inohara, Y Ogura, A Fontalba, O Gutierrez, F Pons, J Crespo, K Fukase, …

    • Year: 2003

    • Citations: 2,245

  • Modeling NAFLD disease burden in 8 countries (2016–2030)

    • Authors: C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, …

    • Year: 2018

    • Citations: 2,027

  • A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

    • Authors: HSA Newsome, PN Buchholtz, K Cusi, M Linder, T Okanoue, V Ratziu, S Sanyal, …

    • Year: 2021

    • Citations: 1,673

  • Obeticholic acid for the treatment of NASH: Phase 3 trial analysis

    • Authors: ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, …

    • Year: 2019

    • Citations: 1,286

  • Elafibranor resolves NASH without fibrosis worsening

    • Authors: SA Ratziu, V Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, …

    • Year: 2016

    • Citations: 1,217

  • Sofosbuvir and ribavirin in HCV genotypes 2 and 3

    • Authors: ER Zeuzem, S Dusheiko, GM Salupere, R Mangia, A Flisiak, RH Hyland, …

    • Year: 2014

    • Citations: 1,048

  • A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis

    • Authors: Not listed

    • Year: 2024

    • Citations: 983

  • Gene expression of TNF-α and TNF receptors in NASH patients

    • Authors: J Crespo, A Cayón, P Fernández‐Gil, M Hernández‐Guerra, M Mayorga, …

    • Year: 2001

    • Citations: 971

  • Advancing the global public health agenda for NAFLD: Consensus statement

    • Authors: JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, …

    • Year: 2022

    • Citations: 683

Alexander Kirichenko | Health Professions | Best Researcher Award

Prof. Dr. Alexander Kirichenko | Health Professions | Best Researcher Award

Professor Drexel University College of Medicine Drexellat at Allegheny General Hospital, United States

Dr. Alexander V. Kirichenko, MD, PhD, is a distinguished radiation oncologist and researcher with extensive expertise in stereotactic body radiotherapy (SBRT) and radiation biology. He currently serves as an Attending Radiation Oncologist at Allegheny General Hospital and System Director for Stereotactic Body Radiotherapy & Gastrointestinal Cancers Program at Allegheny Health Network Cancer Institute. With a career spanning over four decades, Dr. Kirichenko has made significant contributions to oncology research, particularly in hepatocellular carcinoma and functional treatment planning. His humanitarian efforts include leading international collaborations to advance radiation oncology care in Ukraine. A dedicated educator and innovator, Dr. Kirichenko has contributed to multiple clinical trials, patents, and book chapters, shaping the future of radiation oncology.

Professional Profile

Education

Dr. Kirichenko earned his MD from Kyiv Medical University, Ukraine, in 1981, followed by a residency in Radiation Oncology and Nuclear Medicine. He later obtained a PhD in Radiation Biology and a D.Sc. in Radiation Medicine. In pursuit of advanced training, he completed a postdoctoral fellowship at MD Anderson Cancer Center and obtained U.S. medical licensure from the University of Virginia. His residency training in General Surgery and Radiation Oncology at the University of Virginia further solidified his expertise. These rigorous academic and clinical experiences have enabled him to excel in both patient care and research.

Professional Experience

With a career dedicated to radiation oncology, Dr. Kirichenko has held various prestigious academic and clinical positions. He served as an Associate Professor at the Ukrainian National Cancer Institute and the University of Virginia before joining Allegheny General Hospital in 2006. As a leading expert, he has been involved in the development of advanced radiation therapies, including SBRT for liver malignancies. His work also extends to international collaborations, where he has played a pivotal role in enhancing global cancer care standards. His leadership within multiple healthcare institutions has made a lasting impact on cancer treatment methodologies.

Research Interests

Dr. Kirichenko’s research primarily focuses on radiation-induced toxicity, functional treatment planning, and advanced imaging techniques in radiation therapy. His studies on SBRT for hepatocellular carcinoma have contributed to improving survival outcomes while minimizing toxicity. He has also explored the use of superparamagnetic iron oxide nanoparticles (SPION) for enhancing MRI-guided radiotherapy. Through his involvement in numerous clinical trials and NIH-funded studies, he has pioneered innovative approaches in liver and rectal cancer treatment. His research continues to influence clinical practices, bridging the gap between experimental oncology and patient-centered care.

Awards and Honors

Throughout his career, Dr. Kirichenko has received numerous accolades for his contributions to radiation oncology. He has been recognized as one of the Best Doctors in America (2013–2023) and has received the Health Care Heroes Award from Pittsburgh Business Times. His leadership in national and international oncology projects has earned him appointments to expert panels, including the National Center for Biosecurity and Biodefense Preparedness. His extensive list of invited lectures, patents, and book chapters further reflects his commitment to advancing cancer research and treatment.

Conclusion

Dr. Alexander V. Kirichenko is a highly qualified and impactful researcher in radiation oncology with strong contributions to clinical innovation, translational research, and international collaboration. His extensive body of work, patents, leadership roles, and humanitarian contributions make him a strong candidate for the Best Researcher Award. If supplemented with further high-impact publications, mentorship initiatives, and policy engagements, his profile would be nearly unbeatable.

Publications Top Notes

  • Title: Chronomodulated chemotherapy and irradiation: An idea whose time has come?

  • Authors:

    • Tyvin A. Rich

    • Charles H. Shelton III

    • Alexander V. Kirichenko

    • Martin Straume

  • Journal: Chronobiology International

  • Year of Publication: 2002

  • Citations: 18 (as per available sources)

 

Carolin C. Hack | Medicine and Dentistry | Best Scholar Award

Dr. Carolin C. Hack | Medicine and Dentistry | Best Scholar Award

Deputy clinical director at Erlangen University Hospital Women’s Clinic, Germany

Priv.-Doz. Dr. med. Carolin Christine Hack is an accomplished medical professional and the Deputy Director of the Women’s Clinic at the University Hospital Erlangen. With a specialization in gynecological oncology and integrative medicine, Dr. Hack combines her clinical expertise with a passion for patient-centered care. Her innovative approach to medicine, along with her extensive training and research, positions her as a leading figure in her field.

Profile

Scopus

Education 🎓

Dr. Hack completed her medical degree at Friedrich-Alexander University Erlangen-Nuremberg, where she also pursued her habilitation in “Integrative Medicine in the Treatment of Gynecological Oncology Patients.” Her academic journey included a comprehensive curriculum that laid the groundwork for her clinical and research interests, ultimately leading to a robust foundation in both conventional and integrative medicine.

Experience 💼

With over a decade of experience at the University Hospital Erlangen, Dr. Hack has advanced through various roles, from assistant physician to Deputy Director of the Women’s Clinic. She has managed quality assurance initiatives and specialized in integrative medicine, focusing on the intersection of traditional and complementary therapies in patient care. Her leadership in the clinic has fostered a collaborative environment that emphasizes innovative treatment methodologies.

Research Interests 🔍

Dr. Hack’s research primarily focuses on integrative medicine and complementary therapy methods, with a specific emphasis on mammographic density as a risk factor for breast cancer. Her work seeks to enhance patient outcomes through evidence-based practices that incorporate holistic approaches to treatment.

Awards 🏆

Dr. Hack’s contributions to gynecological oncology have been recognized with multiple awards, including:

  • 2015: Klaus-Dieter-Schulz-Versorgungsforschungspreis
  • 2016: First Science Award from the German Society for Senology
  • 2018: Award from the Foundation for Women and Child Health
  • 2022: Research Award for Complementary Medicine from NATUM e.V.

Publications 📚

Dr. Hack has an extensive publication record, including:

  • The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
    • Authors: Ziegler, P., Hartkopf, A.D., Wallwiener, M., Schneeweiss, A., Goossens, C.
    • Journal: BMC Cancer
    • Year: 2024
    • Volume: 24(1), Article 1284
  • Tumor-Associated Neutrophils Are a Negative Prognostic Factor in Early Luminal Breast Cancers Lacking Immunosuppressive Macrophage Recruitment
    • Authors: Schmidt, E., Distel, L., Erber, R., Fietkau, R., Schnellhardt, S.
    • Journal: Cancers
    • Year: 2024
    • Volume: 16(18), Article 3160
  • Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole
    • Authors: Fasching, P.A., Hack, C.C., Nabieva, N., Fehm, T.N., Häberle, L.
    • Journal: European Journal of Cancer
    • Year: 2024
    • Volume: 209, Article 114239
  • Correlation of RANK and RANKL with mammographic density in primary breast cancer patients
    • Authors: Wunderle, M., Heindl, F., Behrens, A.S., Fasching, P.A., Emons, J.
    • Journal: Archives of Gynecology and Obstetrics
    • Year: 2024
    • Volume: 310(2), pp. 1223–1233
  • CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – An Overview of Current Programs
    • Authors: Schneeweiss, A., Brucker, S.Y., Huebner, H., Fehm, T.N., Fasching, P.A.
    • Journal: Geburtshilfe und Frauenheilkunde
    • Year: 2024
    • Volume: 84(5), pp. 443–458
  • Initial experience with a next-generation low-field MRI scanner: Potential for breast imaging?
    • Authors: Dietzel, M., Laun, F.B., Heiß, R., Uder, M., Ohlmeyer, S.
    • Journal: European Journal of Radiology
    • Year: 2024
    • Volume: 173, Article 111352
  • Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer
    • Authors: Heger, L., Heidkamp, G.F., Amon, L., Beckmann, M.W., Dudziak, D.
    • Journal: OncoImmunology
    • Year: 2024
    • Volume: 13(1), Article 2296713
  • Predicting mammographic density with linear ultrasound transducers
    • Authors: Behrens, A., Fasching, P.A., Schwenke, E., Beckmann, M.W., Emons, J.
    • Journal: European Journal of Medical Research
    • Year: 2023
    • Volume: 28(1), Article 384
  • Evaluation of automated techniques for extraction of circulating cell-free DNA for implementation in standardized high-throughput workflows
    • Authors: Lehle, S., Emons, J., Hack, C.C., Ruebner, M., Huebner, H.
    • Journal: Scientific Reports
    • Year: 2023
    • Volume: 13(1), Article 373
  • Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study
    • Authors: Hack, C.C., Maass, N., Aktas, B., Hein, A., Fasching, P.A.
    • Journal: Geburtshilfe und Frauenheilkunde
    • Year: 2023
    • Volume: 84(2), pp. 185–195

Conclusion ✨

Priv.-Doz. Dr. med. Carolin Christine Hack is an exemplary candidate for the Best Researcher Award. Her innovative contributions to integrative medicine and gynecological oncology, coupled with her extensive publication record and commitment to patient care, position her as a leader in her field. By addressing areas for improvement, such as interdisciplinary collaboration and public engagement, Dr. Hack can further enhance her impact in research and continue to advance the frontiers of medical knowledge.

Rima Isaifan | human health | Women Researcher Award

Assoc. Prof. Dr. Rima Isaifan | human health | Women Researcher Award

Associate Professor, Cambridge C University, Qatar

🌿 Dr. Rima Isaifan is an Associate Professor of Environmental Sciences at Cambridge Corporate University, Lucerne, Switzerland. With a Ph.D. in Chemical and Biological Engineering from the University of Ottawa, she has made significant contributions to the fields of sustainable development and environmental protection. Her extensive research focuses on climate change, greenhouse gas emissions, and sustainable urban development, particularly in the Middle Eastern context. 🌍

Publication Profile

Scopus

Education

🎓 Dr. Isaifan earned her Ph.D. in Chemical Engineering (Chemical and Biological Engineering) from the University of Ottawa in 2014. Her academic background blends environmental and chemical sciences, making her an expert in sustainable environmental solutions.

Experience

💼 Currently an Associate Professor at Cambridge Corporate University, Switzerland, Dr. Isaifan has a wealth of teaching and research experience in environmental sciences. She has also collaborated with multiple research institutions, contributing her knowledge to various climate and sustainability initiatives in the Middle East.

Research Focus

🔬 Dr. Isaifan’s research revolves around environmental sustainability, climate change, and the social cost of greenhouse gas emissions. She has also explored urban development strategies, especially in the Middle East, focusing on sustainable transportation and urban renewal projects. Her work aims to create practical solutions to mitigate climate change. 🌱

Awards and Honors

🏅 Dr. Isaifan’s outstanding contributions to environmental research and sustainability have earned her recognition in academic and professional communities. She continues to push boundaries in environmental policy and science, especially regarding climate change action in Arab countries. 🌍

Publication Highlights

📚 Dr. Isaifan has published extensively in top-tier journals. Some of her notable works include:

Transit-Oriented Development in Middle Eastern Cities: The Urban Renewal Framework for the Souq Waqif in Doha, Qatar (2024) in Urban Science, DOI: 10.3390/urbansci8040182

Correction: Al-Jabir, M.; Isaifan, R.J. Long-Term Projection of Transport-Related Social Cost of Greenhouse Gas Emissions in Qatar (2024) in Sustainability, DOI: 10.3390/su16198422

Strategic plans to support action against climate change in the Arab countries in the Middle East Region (2024) in Journal of Sustainable Development Law and Policy, DOI: 10.4314/jsdlp.v15i1.11

Long-Term Projection of Transport-Related Social Cost of Greenhouse Gas Emissions in Qatar (2024) in Sustainability, DOI: 10.3390/su16020536

 

Shahab Reaeian | Prevention | Best Researcher Award

Assoc Prof Dr. Shahab Reaeian | Prevention | Best Researcher Award

Academic member, Kermanshah University of Medical Sciences, Iran

Dr. Shahab Rezaeian is an esteemed epidemiologist from Iran, specializing in public health and epidemiology. With a PhD from Shiraz University of Medical Sciences, he has dedicated his career to understanding the dynamics of diseases and their impact on communities. He is currently a faculty member at Kermanshah University of Medical Sciences, contributing to the field through both research and education. 🩺📚

Publication Profile

Google scholar

Education

Dr. Rezaeian earned his B.S. in Public Health from Iran University of Medical Sciences in 2007, followed by an MSc in Epidemiology from Hamadan University of Medical Sciences in 2012. He completed his PhD in Epidemiology at Shiraz University of Medical Sciences in 2016, focusing his research on the survival trends and blood demand of beta-thalassemia patients. 🎓

Experience

Dr. Rezaeian has extensive experience in epidemiological research, particularly in assessing the risk factors for various health conditions, including congenital hypothyroidism and HIV. His professional journey reflects a commitment to advancing public health through rigorous data analysis and interpretation. 💼

Research Focus

His primary research interests include epidemiological modeling, public health interventions, and the study of congenital conditions. Dr. Rezaeian aims to contribute to effective health policies and practices by analyzing health data and identifying key determinants of health outcomes. 🔬📈

Awards and Honours

Dr. Rezaeian has received several accolades for his contributions to epidemiology and public health, including recognition for his impactful research publications and involvement in various health initiatives. His work continues to inspire future generations of health professionals. 🏆

Publication Top Notes

Dr. Rezaeian has authored numerous significant publications in reputable journals, contributing to the scientific community’s understanding of epidemiology and public health. Some notable works include:

Influenza A (H1N1) in Hamedan Province, Western Iran in 2009: A Case-Control Study (2010, J Res Health Sci) – Cited by 30

Quality of Cohort Studies Reporting Post the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (2011, Epidemiology and Health) – Cited by 50

The Quality of the Reporting of Randomized Controlled Trials after CONSORT Statement in the Prestigious Journals (2013, Shiraz E Medical Journal) – Cited by 40

Difference in the Incidence of Congenital Hypothyroidism Among World Countries (2013, Ann Saudi Med) – Cited by 20

Social Determinants of Health Associated with Self-Reported HIV Testing Among Women (2013, Iran J Public Health) – Cited by 35

Risk Factors of Congenital Hypothyroidism Using Propensity Score: A Matched Case-Control Study (2013, J Res Health Sci) – Cited by 25